[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Matusewicz et al., 2022 - Google Patents

COVID-19 therapies: do we see substantial progress?

Matusewicz et al., 2022

View HTML @Full View
Document ID
8018905535800222708
Author
Matusewicz L
Golec M
Czogalla A
Kuliczkowski K
Konka A
Zembala-John J
Sikorski A
Publication year
Publication venue
Cellular & Molecular Biology Letters

External Links

Snippet

The appearance of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its spread all over the world is the cause of the coronavirus disease 2019 (COVID-19) pandemic, which has recently resulted in almost 400 million confirmed cases and 6 million …
Continue reading at link.springer.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application

Similar Documents

Publication Publication Date Title
Fung et al. Similarities and dissimilarities of COVID-19 and other coronavirus diseases
Pizzato et al. SARS-CoV-2 and the host cell: a tale of interactions
Santos et al. Antivirals against coronaviruses: candidate drugs for SARS-CoV-2 treatment?
Cannalire et al. Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities
Shyr et al. Drug discovery strategies for SARS-CoV-2
Gil et al. COVID-19: drug targets and potential treatments
Prajapat et al. Drug targets for corona virus: A systematic review
Zhou et al. Potential therapeutic targets and promising drugs for combating SARS‐CoV‐2
Alipoor et al. COVID-19: molecular and cellular response
Sohag et al. Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review
Shang et al. Antiviral drug discovery for the treatment of enterovirus 71 infections
Su et al. Molecular Insights into Small‐Molecule Drug Discovery for SARS‐CoV‐2
Kumar et al. Anti-SARS coronavirus agents: a patent review (2008–present)
Senger et al. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery
Das et al. An overview of key potential therapeutic strategies for combat in the COVID-19 battle
Rajarshi et al. Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19
Vlachakis et al. Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic
Muhammed Molecular targets for COVID-19 drug development: enlightening Nigerians about the pandemic and future treatment
Jamalipour Soufi et al. Potential inhibitors of SARS-CoV-2: recent advances
Singh et al. SARS-CoV-2 therapeutics: how far do we stand from a remedy?
Pluskota-Karwatka et al. Reducing SARS-CoV-2 pathological protein activity with small molecules
Simabuco et al. Molecular mechanisms and pharmacological interventions in the replication cycle of human coronaviruses
Manhas et al. Covid-19 pandemic and current medical interventions
Gao et al. Antiviral peptides with in vivo activity: Development and modes of action
Matusewicz et al. COVID-19 therapies: do we see substantial progress?